Clinical Trials Logo

Leukemia, Myeloid, Acute clinical trials

View clinical trials related to Leukemia, Myeloid, Acute.

Filter by:

NCT ID: NCT00981240 Completed - Clinical trials for Acute Myelogenous Leukemia

Dose Escalation, Safety and Pharmacokinetic Study of SAR103168 in Patients Refractory/ Relapsed Acute Leukemias or High-risk Myelodysplastic Syndromes

Start date: September 2009
Phase: Phase 1
Study type: Interventional

Primary objectives: - To determine the maximum tolerated dose (MTD) of SAR103168 and to characterize the dose limiting toxicities (DLTs) in the proposed dose regimen - To evaluate the pharmacokinetic (PK) profile of SAR103168 Secondary objectives: - To characterize the global safety profile of SAR103168 - To evaluate preliminary anti-leukemia activity - To investigate the potential induction effect on CYP3A4 and persistence of this effect by using oral midazolam as a probe substrate in patients enrolled into the expanded cohort at the MTD - To determine the metabolic pathways of SAR103168 and identify the chemical structures of metabolites - To determine the potential impact of SAR103168 on the QTc interval in patients enrolled at the MTD

NCT ID: NCT00977782 Completed - Clinical trials for Acute Myeloid Leukemia

Open-label Multicenter Study of PKC412 in Pts With AML and MDS With Either Wild-type or Mutated FLT3

Start date: March 2003
Phase: Phase 1/Phase 2
Study type: Interventional

This study will assess the safety, tolerability, and pharmacokinetics in AML and high risk MDS patients with either wild type or mutated FLT3 using PKC412 with intra-patient dose escalation.

NCT ID: NCT00975975 Completed - Multiple Myeloma Clinical Trials

Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer

Start date: September 2009
Phase: Phase 2
Study type: Interventional

The purpose of this study is to compare the effects (good and bad) of the medication basiliximab in combination with cyclosporine (investigational therapy) for the prevention of a complication of bone marrow transplantation known as graft-versus-host disease (GVHD). GVHD is a complication in which the cells of the transplanted bone marrow react against organs and tissues.

NCT ID: NCT00969891 Completed - Clinical trials for Acute Myeloid Leukemia

Study of Dosage Individualisation for the Treatment of Acute Myeloid Leukemia

Start date: September 2009
Phase: N/A
Study type: Observational

The present study is not hypothesis driven but will explore the ability of pharmacokinetic-pharmacodynamic modelling to predict optimal dosage of the chemotherapeutic drugs used in therapy in adult patients with acute myeloid leukemia.

NCT ID: NCT00968071 Completed - Clinical trials for Myelodysplastic Syndrome

Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-risk Myelodysplastic Syndrome

Start date: February 2008
Phase: Phase 2
Study type: Interventional

The goal of this clinical research study is to learn if giving 5-aza-2 deoxycytidine (decitabine) in combination with Mylotarg (gemtuzumab ozogamicin) can help to control AML or high-risk MDS. The safety of this drug combination will also be studied.

NCT ID: NCT00964873 Completed - Clinical trials for Acute Myeloid Leukemia

A Phase 1 Study of the HSP90 Inhibitor, STA-9090 in Subjects With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Blast-phase Chronic Myelogenous Leukemia

Start date: August 2009
Phase: Phase 1
Study type: Interventional

An open-label phase 1 study to assess safety and efficacy of once-weekly STA-9090 (ganetespib) in subjects with AML, ALL and blast-phase CML.

NCT ID: NCT00963521 Completed - Leukemia Clinical Trials

Vaccine Therapy in Treating Patients With Acute Myeloid Leukemia in Complete Remission

Start date: June 2008
Phase: Phase 1
Study type: Interventional

RATIONALE: Vaccines made from dendritic cells may help the body build an effective immune response to kill cancer cells. PURPOSE: This phase I trial is studying the side effects of vaccine therapy and to see how well it works in treating patients with acute myeloid leukemia in complete remission.

NCT ID: NCT00962767 Completed - Clinical trials for Leukemia, Myelocytic, Acute

Comparison of Two Treatments in Intermediate and High-risk Acute Promyelocytic Leukemia (APL) Patients to Assess Efficacy in 1st Hematological Complete Remission and Molecular Remission

Start date: May 2002
Phase: Phase 3
Study type: Interventional

The study will compare the efficacy of the 2 treatments in intermediate and high-risk APL patients in achieving first hematological complete remission and molecular remission.

NCT ID: NCT00957385 Completed - Clinical trials for Acute Myeloid Leukemia

Maintenance Therapy in Acute Myeloid Leukemia (AML) Patients

Start date: June 2008
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine if Revlimid will help maintain patients with acute myeloid leukemia in remission.

NCT ID: NCT00955916 Completed - Leukemia Clinical Trials

CLAG Gleevec in Relapsed or Refractory Acute Myeloid Leukemia (AML)

Start date: August 2009
Phase: Phase 2
Study type: Interventional

The purpose of the study is to find out what effects (good and bad) Gleevec® (Imatinib mesylate) combined with chemotherapy has on participants and their acute myeloid leukemia.